M FRANCOIS ROCHE

Rhumatologue

RPPS 10001307411

📊 Reconnaissance scientifique : 2/100📝 14 articles publiés🇫🇷 Publications académiques françaises (6)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

2 articles ont été cités au moins 2fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Articles de presse (8)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

Loir-et-Cher : Xavier Gervoson, président fondateur de St Michel n’est plus - lanouvellerepublique.fr

📰 lanouvellerepublique.fr · 17/03/2026

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxQc0VHNGtNMDNvMlhPaFlsNWQ5Q01sd1RESXlGdU5RVHpOTmdvVWp0U3daX0hURlItdC0wbm1IUzRrNkY1NThDUktEbFF5dDhvRW1OUlJ1VTZRUmZXR1U2aXVoUWMxa3pzTzg1eUc0NGJPWFo2XzY3ZTBaOUxkNm5yZWVjN005UVdCQkFxb2F4azZqc2xvakRLVUk4dy1TUEZwXzF6SlFCWG9PRlVPZHVsQzBHak4xeExEem

Municipales 2026 à Marseille. Qui sont les candidats dans les 15e et 16e arrondissements ? - Actu.fr

📰 Actu.fr · 12/03/2026

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPTmx2TElzR0FQZlZDMzAxSVQ0YVJ3UE9HUnFzZnRiTGY2eUNMbk96QTVPTFVqRzRvVnNMbnZIQTIzRXNsblVJelhOQk1sM0EzWC1TcnFMU3AxNFRJOEY1a3FkVWRHTU5zZjBpQzFKcHhPQk56akJPaHpZd2lCUTlNQ3Q5Q24xSFZZRTVlVXJxdGdsR3lfV0doQ3hXNTJjSVl0TUNtakZWMXJVUW1VZkxpdldCMEJNRXJRcm

"Qui veut être mon associé ?" : un entrepreneur originaire de Nantes sur M6 - Actu.fr

📰 Actu.fr · 04/02/2026

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUHJUZkh5QmRCQjB1RzFjLXRXVkVsMk5ET3lFYnN1aDZJQWthOWNnd1djb1d5TTVpYUdVeUx6YUZEVHZMMHk0ZktjNG9CZWdWa0xpM2dkNWtHV0NsYlhXczFuaU1kRDI5by0zeVVuc1BucDFnT252aHVyWGRpcTlEeVJOSGRzLWI3bUhGREgyRlVjXzVQYXdSRHY3dExMZ2YtTlJIcDFtb25qUDctZHZfRVNVT2I2NEltTE

Coala, la blouse qui soulage les soignants et les aidants - L'Essentiel de l'Éco

📰 L'Essentiel de l'Éco · 29/01/2026

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPMEtnTDZ6UnA1Ty0zY1BTYzAwSTd6UWNnWGVKRVJ0cS12bkZmbXNxSURaaWFLWlhRRzc4UEtRazR1RnlRT196Z0dYSXhSOVJGU3M4N21lSmROWV9FQmpfV2hobks2YkJfSFRtb3R2NV96ZFNDVk15UlBXamZqX3FVa0pYYk5wSXRYQ2Fqa1JybHJvOWxZ?oc=5" target="_blank">Coala, la blouse qui soulag

La "Bipe", un dispositif de soutien sur-mesure pour les étudiants en médecine à Limoges - Le Populaire du Centre

📰 Le Populaire du Centre · 05/04/2021

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQYzVTZkp2UzVTWnE5U2dOc3RYM1hpMVYycHlsNHNoR3FsRFpWbWFIZlBpYmZESGRPbDVQekc3RjdHRkZWM1RKaHBjYjgxV2hEYWpOdWlyY2VSSVFjTW9UQUZBaTFLMjhnRWNZQjkyVUphRmhUUS1UdXZSOW5ITUR4TWxfV2lWOWU1R2p1ZkZCTkZIcElNSW95QXU1LTZMTks3aFpKb3pyRVJ1WDBBbklNaTUwQWlxTm04UD

Le TCA compte 237 licenciés, dont 107 jeunes - La Montagne

📰 La Montagne · 17/10/2017

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPSEQwN1RvRDNFTXZNaUpYOFlVdlJ6bzJaMklHN1JKOXJiZGt6RlozblBEOTJlR2ppMkZqUVVSZlpmQ1BsOUdDdHpCTEtxbUhKdFNhRE5GaHhtUjRwRFQ4NEFpcWpxREhZUWNWMGJPV3lZNkNxT0lWelpxRGpZTm5IRWpFZTBzY1lyU3Q1Wkxod2Y0bl9obHAxZmdnRElIQm1YNk5J?oc=5" target="_blank">Le TCA

Faute de « repreneurs », le seul cabinet libéral de radiologie de Thiers (Puy-de-Dôme) va fermer en juillet - La Montagne

📰 La Montagne · 26/07/2017

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPOGRYUXNxdkFKeHFjQ0VlTWNqeHpibmRxaTZtQU9kWWFrRVpWWENPaDF3ZjR6aWJVZ29XUEpSVFN1MHhDeEw5aGx1LVBBU3hhal9COUZfa0dac25zb0dsd001cUFsSDk0YlJIVVFadk5ZWllfZnlEMGhWQVowdXZFNjlHQUxIdDRXVzZneTZUQTdHZjN2aG9Wc3VxUHYxYXJDN2U5Z2pBNV81SEFFMFlYd1E2YThuZWhsS3

Jean-Claude Barlaud et son équipe - La Montagne

📰 La Montagne · 10/03/2014

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPb0UxY0NKR2NiZ1VORkxSM2xJc1VDUTVBTnEycE1zWDJkX3RhdUVMX1NkTGs3NVBvN3VPdmtNRG52N3V3UFFtYkU3SjV0OWV2Um5GNGdFYmpTNUVONzQ2TG9RNFVUcFdDa1BlWjFyMzYxLWQzVmMyRGtzRUR2dWFwVHNMeDlUd1FlR3ZLSjhyMHk2eUxqamZtQ21CNA?oc=5" target="_blank">Jean-Claude Barla

Top publications · les plus citées

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Lancet (London, England) · 2023

📚 362 citations🎯 RCR 63.30Top 0% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Hydrocortisone in Severe Community-Acquired Pneumonia

The New England journal of medicine · 2023

📚 313 citations🎯 RCR 44.76Top 0% NIH🩺 Clinique

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Critical care (London, England) · 2022

📚 66 citations🎯 RCR 6.51Top 5% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia was assessed in PA-colonised mechanically ventilated subjects. Methods EVADE (NCT02696902) was a phase 2, randomised, parallel-group, double-blind, placebo-controlled study in Europe, Turkey, Israel, and the USA. Subjects ≥ 18 years old, mechanically ventilated, tracheally colonised with PA, and without new-onset pneumonia, were randomised (1:1:1) to MEDI3902 500, 1500 mg (single intravenous dose), or placebo. The primary efficacy endpoint was the incidence of nosocomial PA pneumonia through 21 days post-dose in MEDI3902 1500 mg versus placebo, determined by an independent adjudication committee. Results Even if the initial sample size was not reached because of low recruitment, 188 subjects were randomised (MEDI3902 500/1500 mg: n = 16/87; placebo: n = 85) between 13 April 2016 and 17 October 2019. Out of these, 184 were dosed (MEDI3902 500/1500 mg: n = 16/85; placebo: n = 83), comprising the modified intent-to-treat set. Enrolment in the 500 mg arm was discontinued due to pharmacokinetic data demonstrating low MEDI3902 serum concentrations. Subsequently, enrolled subjects were randomised (1:1) to MEDI3902 1500 mg or placebo. PA pneumonia was confirmed in 22.4% (n = 19/85) of MEDI3902 1500 mg recipients and in 18.1% (n = 15/83) of placebo recipients (relative risk reduction [RRR]: − 23.7%; 80% confidence interval [CI] − 83.8%, 16.8%; p = 0.49). At 21 days post-1500 mg dose, the mean (standard deviation) serum MEDI3902 concentration was 9.46 (7.91) μg/mL, with 80.6% (n = 58/72) subjects achieving concentrations > 1.7 μg/mL, a level associated with improved outcome in animal models. Treatment-emergent adverse event incidence was similar between groups. Conclusions The bivalent, bispecific monoclonal antibody MEDI3902 (gremubamab) did not reduce PA nosocomial pneumonia incidence in PA-colonised mechanically ventilated subjects. Trial registration Registered on Clinicaltrials.gov (NCT02696902) on 11th February 2016 and on EudraCT (2015-001706-34) on 7th March 2016.

Cookies & analyse de trafic

M FRANCOIS ROCHE

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (8)

Top publications · les plus citées

Publications scientifiques (38) — classées par pathologie

Essai clinique17

Transversal11

Pharmacovigilance5

Activité physique / Rééducation2

Biomarqueurs / Auto-Ac2

Biothérapies non-anti-TNF2

Épidémiologie & registres2

Qualité de vie / PROMs2

Corticothérapie1

Économie santé1

Santé mentale / fatigue1

Vraie vie / RWE1

Partager cette fiche